JP7113023B2 - ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 - Google Patents

６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 Download PDF

Info

Publication number
JP7113023B2
JP7113023B2 JP2019553452A JP2019553452A JP7113023B2 JP 7113023 B2 JP7113023 B2 JP 7113023B2 JP 2019553452 A JP2019553452 A JP 2019553452A JP 2019553452 A JP2019553452 A JP 2019553452A JP 7113023 B2 JP7113023 B2 JP 7113023B2
Authority
JP
Japan
Prior art keywords
compound
formula
base
obtaining
reacted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019553452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512370A (ja
Inventor
チェン・クァ
イェルク・デーアベルク
ドン・リン
マイケル・ダメルディンガー
バハール・イナンクル
セルゲイ・ブイ・コロトゥチン
ジュン・リ
アマンダ・ジェイ・ロジャーズ
ビクター・ダブリュー・ロッソ
エリック・エム・シモンズ
マキシム・シー・ディ・スメイヨン
ダニエル・エス・トライトラー
ジャンジー・ワン
ビン・ジェン
マイケル・ジェイ・スミス
ニール・エイ・ストロットマン
スティーブン・ティモンコ
タマス・ベンコビックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2020512370A publication Critical patent/JP2020512370A/ja
Priority to JP2022117894A priority Critical patent/JP7457758B2/ja
Application granted granted Critical
Publication of JP7113023B2 publication Critical patent/JP7113023B2/ja
Priority to JP2023208420A priority patent/JP7837938B2/ja
Priority to JP2025284416A priority patent/JP2026067880A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/04—Mono-, di- or tri-methylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2019553452A 2017-03-30 2018-03-29 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 Active JP7113023B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022117894A JP7457758B2 (ja) 2017-03-30 2022-07-25 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
JP2023208420A JP7837938B2 (ja) 2017-03-30 2023-12-11 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
JP2025284416A JP2026067880A (ja) 2017-03-30 2025-12-26 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762478789P 2017-03-30 2017-03-30
US62/478,789 2017-03-30
PCT/US2018/025100 WO2018183649A1 (en) 2017-03-30 2018-03-29 Process for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022117894A Division JP7457758B2 (ja) 2017-03-30 2022-07-25 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法

Publications (2)

Publication Number Publication Date
JP2020512370A JP2020512370A (ja) 2020-04-23
JP7113023B2 true JP7113023B2 (ja) 2022-08-04

Family

ID=62002470

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019553452A Active JP7113023B2 (ja) 2017-03-30 2018-03-29 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
JP2019553556A Active JP7260481B2 (ja) 2017-03-30 2018-03-29 ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１Ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－Ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態
JP2022117894A Active JP7457758B2 (ja) 2017-03-30 2022-07-25 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
JP2023010810A Active JP7476370B2 (ja) 2017-03-30 2023-01-27 ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１Ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－Ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態
JP2023208420A Active JP7837938B2 (ja) 2017-03-30 2023-12-11 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
JP2025284416A Pending JP2026067880A (ja) 2017-03-30 2025-12-26 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2019553556A Active JP7260481B2 (ja) 2017-03-30 2018-03-29 ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１Ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－Ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態
JP2022117894A Active JP7457758B2 (ja) 2017-03-30 2022-07-25 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
JP2023010810A Active JP7476370B2 (ja) 2017-03-30 2023-01-27 ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１Ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－Ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態
JP2023208420A Active JP7837938B2 (ja) 2017-03-30 2023-12-11 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
JP2025284416A Pending JP2026067880A (ja) 2017-03-30 2025-12-26 ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法

Country Status (23)

Country Link
US (5) US20200239449A1 (https=)
EP (4) EP3601268B1 (https=)
JP (6) JP7113023B2 (https=)
KR (4) KR102642407B1 (https=)
CN (4) CN110475774B (https=)
AU (3) AU2018244451B2 (https=)
CA (2) CA3058209A1 (https=)
CY (1) CY1124194T1 (https=)
DK (1) DK3601268T3 (https=)
EA (2) EA201992308A1 (https=)
ES (2) ES2970229T3 (https=)
HR (1) HRP20210764T1 (https=)
HU (1) HUE054886T2 (https=)
IL (3) IL269586B (https=)
LT (1) LT3601268T (https=)
MX (4) MX2019011231A (https=)
PL (1) PL3601268T3 (https=)
PT (1) PT3601268T (https=)
RS (1) RS61816B1 (https=)
SG (2) SG11201909018VA (https=)
SI (1) SI3601268T1 (https=)
SM (1) SMT202100239T1 (https=)
WO (2) WO2018183656A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
US12570637B2 (en) 2019-06-12 2026-03-10 Bristol-Myers Squibb Company Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide
JP7812785B2 (ja) 2019-09-18 2026-02-10 ブリストル－マイヤーズ スクイブ カンパニー Ｔｙｋ２阻害薬の剤形
CN114787152A (zh) * 2019-12-27 2022-07-22 苏州科睿思制药有限公司 一种bms-986165晶型及其制备方法和用途
WO2021143430A1 (zh) * 2020-01-19 2021-07-22 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型及其制备方法和用途
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
WO2021170046A1 (en) * 2020-02-26 2021-09-02 Beigene, Ltd. Tyk-2 inhibitor
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
KR20230042278A (ko) 2020-06-22 2023-03-28 베이진 엘티디 Tyk-2 저해제
CN115667246B (zh) * 2020-07-24 2024-08-23 上海翰森生物医药科技有限公司 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用
WO2022021684A1 (zh) * 2020-07-31 2022-02-03 苏州科睿思制药有限公司 一种bms-986165盐酸盐晶型csv及其制备方法和用途
IL301389A (en) 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for tyk2 inhibitors comprising swellable cores
WO2022083649A1 (zh) * 2020-10-20 2022-04-28 杭州领业医药科技有限公司 哒嗪衍生物的晶型
KR20230137962A (ko) * 2021-01-29 2023-10-05 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
EP4387968B1 (en) 2021-08-20 2025-11-12 Bristol-Myers Squibb Company Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
EP4404930A1 (en) * 2021-09-23 2024-07-31 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
JP2024539703A (ja) 2021-10-28 2024-10-29 ブリストル－マイヤーズ スクイブ カンパニー デュークラバシチニブの局所製剤
EP4441043A1 (en) 2021-12-01 2024-10-09 Teva Czech Industries s.r.o Solid state forms of deucravacitinib, deucravacitinib hcl and process for preparation of deucravacitinib and intermediates
US12222104B2 (en) * 2022-03-21 2025-02-11 General Electric Company Turbine engine combustor and combustor liner
WO2023181075A1 (en) * 2022-03-24 2023-09-28 Dr. Reddy's Laboratories Limited Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof
CN114989103B (zh) * 2022-06-09 2024-07-09 杭州科巢生物科技有限公司 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法
CN117447411B (zh) * 2022-07-18 2025-12-23 苏州鹏旭医药科技有限公司 一种杂环药物中间体的合成方法
WO2024017150A1 (zh) * 2022-07-18 2024-01-25 苏州鹏旭医药科技有限公司 一种氘可来昔替尼的合成方法
WO2024088282A1 (zh) * 2022-10-28 2024-05-02 浙江华海药业股份有限公司 一种哒嗪酰胺类化合物、其药物组合物及其作为tyk2抑制剂的用途
EP4713315A1 (en) * 2023-05-15 2026-03-25 Alivus Life Sciences Limited Process for the preparation of deucravacitinib, and crystalline forms thereof
EP4538259A1 (en) 2023-10-09 2025-04-16 Farmhispania Group, S.L. Processes for the preparation of deucravacitinib
WO2025131031A1 (zh) * 2023-12-22 2025-06-26 上海奥博生物医药股份有限公司 一种TyK2抑制剂及其中间体的制备方法
WO2025173029A1 (en) * 2024-02-14 2025-08-21 Natco Pharma Limited An improved process for the preparation of deucravacitinib
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
WO2025259267A1 (en) 2024-06-11 2025-12-18 Vector Vitale Ip Llc Pharmaceutical compositions for modulating inflammation and oxidative stress comprising chemically enriched elements
ES3059443A1 (es) 2024-09-17 2026-03-20 Moehs Iberica Sl Forma solida de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)piridazine-3-carboxilato de metilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de deucravacitinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506369A (ja) 2012-11-08 2016-03-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023649B2 (ja) 1976-09-08 1985-06-08 東ソー株式会社 臭化水素酸による臭化メチルの製造方法
JPS5455501A (en) 1977-10-05 1979-05-02 Toyo Soda Mfg Co Ltd Continuous preparation of methyl bromide
US4254061A (en) * 1979-09-11 1981-03-03 E. I. Du Pont De Nemours And Company Preparation of monomethylamine
ATE288420T1 (de) * 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
CN100579579C (zh) 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
CA2549385A1 (en) 2003-12-22 2005-07-21 Eli Lilly And Company Triazole, oxadiazole and thiadiazole derivative as ppar modulators for the treatment of diabetes
EP1931466B1 (de) * 2005-09-29 2012-11-14 Basf Se Formkörper enthaltend ein alumosilikat und aluminiumoxid und verfahren zur kontinuierlichen herstellung von methylaminen
KR20090111847A (ko) 2007-01-19 2009-10-27 아디아 바이오사이언스즈 인크. Ｍｅｋ 억제제
BR112012006956A2 (pt) * 2009-10-12 2015-09-15 Bayer Cropscience Ag 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas
EP2542089B1 (en) * 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
JP5433087B2 (ja) * 2010-03-18 2014-03-05 ▲蘇▼州▲澤▼▲ジン▼生物制▲薬▼有限公司 重水素化メチルアミン及びその塩の製造方法
WO2013047813A1 (ja) 2011-09-30 2013-04-04 大鵬薬品工業株式会社 １，２，４－トリアジン－６－カルボキサミド誘導体
WO2013091011A1 (en) * 2011-12-21 2013-06-27 Biota Europe Ltd Heterocyclic urea compounds
CN104159891B (zh) 2012-01-10 2016-09-07 霍夫曼-拉罗奇有限公司 哒嗪酰胺化合物和它们作为syk 抑制剂的用途
WO2013171643A1 (en) 2012-05-14 2013-11-21 Piramal Enterprises Limited An improved process for preparation of irbesartan
KR102233252B1 (ko) * 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物
JP7113023B2 (ja) * 2017-03-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
KR102848769B1 (ko) * 2018-05-31 2025-08-20 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태
JP7631193B2 (ja) * 2018-10-22 2025-02-18 アルミス インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
KR20230137962A (ko) * 2021-01-29 2023-10-05 브리스톨-마이어스 스큅 컴퍼니 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3)피리다진-3-카르복스아미드의 결정 형태
CN117377667A (zh) * 2021-03-29 2024-01-09 百时美施贵宝公司 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506369A (ja) 2012-11-08 2016-03-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物

Also Published As

Publication number Publication date
JP2024037836A (ja) 2024-03-19
WO2018183656A1 (en) 2018-10-04
MX2022010495A (es) 2022-09-21
US20210371404A1 (en) 2021-12-02
AU2018244451B2 (en) 2022-03-10
IL269594B1 (en) 2023-10-01
RS61816B1 (sr) 2021-06-30
JP7457758B2 (ja) 2024-03-28
US12545665B2 (en) 2026-02-10
LT3601268T (lt) 2021-05-25
EP4296258A3 (en) 2024-03-20
SG11201908947QA (en) 2019-10-30
CN116354939A (zh) 2023-06-30
EA201992300A1 (ru) 2020-02-20
AU2018244451A1 (en) 2019-11-21
MX2019011231A (es) 2019-11-18
EP3882237A2 (en) 2021-09-22
MX392693B (es) 2025-03-12
US12565487B2 (en) 2026-03-03
CN116813561A (zh) 2023-09-29
KR102642407B1 (ko) 2024-02-28
US20210107897A1 (en) 2021-04-15
EP4296258A2 (en) 2023-12-27
JP7837938B2 (ja) 2026-03-31
JP7476370B2 (ja) 2024-04-30
PL3601268T3 (pl) 2021-07-05
CA3058209A1 (en) 2018-10-04
JP2020512370A (ja) 2020-04-23
PT3601268T (pt) 2021-04-13
JP2020512380A (ja) 2020-04-23
KR102857398B1 (ko) 2025-09-08
KR20240154690A (ko) 2024-10-25
JP2023052683A (ja) 2023-04-11
CN110914260A (zh) 2020-03-24
JP7260481B2 (ja) 2023-04-18
IL269586A (en) 2019-11-28
CA3058177A1 (en) 2018-10-04
EP3601270A1 (en) 2020-02-05
US20200109134A1 (en) 2020-04-09
KR20190133725A (ko) 2019-12-03
MX2019011092A (es) 2020-01-20
US11649226B2 (en) 2023-05-16
US20230271946A1 (en) 2023-08-31
ES2970229T3 (es) 2024-05-27
CN110475774B (zh) 2023-06-02
IL269594B2 (en) 2024-02-01
EA201992308A1 (ru) 2020-02-13
SG11201909018VA (en) 2019-10-30
JP2022166011A (ja) 2022-11-01
AU2018244916A1 (en) 2019-11-21
EP3882237A3 (en) 2021-11-03
IL269586B (en) 2022-08-01
JP2026067880A (ja) 2026-04-21
WO2018183649A1 (en) 2018-10-04
SMT202100239T1 (it) 2021-05-07
ES2864450T3 (es) 2021-10-13
EP3882237B1 (en) 2023-12-20
AU2021261839A1 (en) 2021-12-02
EP3601268A1 (en) 2020-02-05
CN110475774A (zh) 2019-11-19
KR20250080914A (ko) 2025-06-05
DK3601268T3 (da) 2021-05-03
US10899745B2 (en) 2021-01-26
HUE054886T2 (hu) 2021-10-28
MX2022010496A (es) 2022-09-21
IL305615A (en) 2023-11-01
IL269594A (en) 2019-11-28
CY1124194T1 (el) 2022-05-27
US20200239449A1 (en) 2020-07-30
BR112019020169A2 (pt) 2020-04-22
AU2021261839B2 (en) 2023-07-20
EP3601268B1 (en) 2021-03-17
AU2018244916B2 (en) 2021-11-18
SI3601268T1 (sl) 2021-07-30
KR20190133726A (ko) 2019-12-03
BR112019020163A2 (pt) 2020-04-22
HRP20210764T1 (hr) 2021-07-09
KR102720054B1 (ko) 2024-10-22

Similar Documents

Publication Publication Date Title
JP7113023B2 (ja) ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
CN117157274A (zh) 奥美卡替莫卡必尔的合成
TW201522334A (zh) 製備細胞凋亡誘導劑的方法
JP7661437B2 (ja) 一酸化窒素を供与するプロスタグランジン類似体の製造方法
CN114901644B (zh) 制备右美托咪定的方法
JP2011519879A (ja) 置換ビフェニルアニリド類を調製する方法
WO2018032586A1 (zh) 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸的合成方法及其中间体
JP2001515496A (ja) ５−アミノメチル−クロロピリジン類の製造方法
BR112019020169B1 (pt) Processo para a preparação de 6- (ciclopropanoamido)-4-((2-metóxi-3- (1-metil-1h-1,2,4- triazol-3-il)fenil)amino)-n-(metil-d3)piridazina-3- carboxamida, intermediários, seus usos e composição farmacêtica
EA040475B1 (ru) СПОСОБ ПОЛУЧЕНИЯ 6-(ЦИКЛОПРОПАНАМИДО)-4-((2-МЕТОКСИ-3-(1-МЕТИЛ-1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ФЕНИЛ)АМИНО)-3-(МЕТИЛ-d3)ПИРИДАЗИН-3-КАРБОКСАМИДА
JP2011500759A (ja) ６−置換−イミダゾ［２，１−ｂ］チアゾール−５−スルホニルハライドの調製方法
JPS6316379B2 (https=)
JP2018525366A (ja) イブルチニブの製法及び新規な合成中間体

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220725

R150 Certificate of patent or registration of utility model

Ref document number: 7113023

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250